Phase 4 N=85 Multimodal Analgesia With Acetaminophen vs. Narcotics Alone After Hip Arthroscopy
Hip Arthroscopy
Primary: Patient Satisfaction — 8.48; 8.83 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=21 Comparison of Local Anesthetic Infusion Pump Versus Depofoam Bupivacaine for Pain Management
Pain, Postoperative
Primary: Total Narcotic Usage — 0.8; .13; 0.18 mg/kg/day morphine
N/A N=75 Excess Opioid Disposal Following Orthopedic Foot and Ankle Surgery
Medication Disposal · Behavior
Primary: Number of Participants Who Safely Disposed The Excess Medication — 8; 22 Participants
N/A N=70 Pain and Safety of Restylane With and Without Lidocaine for Correction of Moderate and Severe Nasolabial Folds
Nasolabial Fold
Primary: Treatment Difference in Pain (Restylane Lidocaine Side - Restylane Side) as Measured by a Visual Analogue Scale(VAS) — 77.1 percentage of subjects
N/A N=14 Release of Nociceptin From Granulocytes in Sepsis
Sepsis · Septic Shock · Sepsis Syndrome
Primary: Proportion of Responsive Biosensor Cells Responding to Granulocyte Addition in the Presence and Absence of NOP Antagonist — 34.25907426; 5.882352941; 44.17193917…
Phase 4 N=224 Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Mean Daily BG Levels — 172; 173 mg/dL
Phase 2 N=56 Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
Hodgkin's Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Panobinostat + ICE — 30 mg
Phase 3 N=652 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)
Pneumococcal Infections
Primary: Percentage of Participants With Solicited Injection-site Adverse Events Following V114 or Prevnar 13™ — 9.8; 5.6; 55.0; 41.4 Percentage of Participants — p=0.043
N/A N=24 Evaluating High Flow Humidification Therapy in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) — 0.056; 0.052; 0.192; 0.194 change in score on a scale
Phase 2 N=107 Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients
Obese Patients With Non-alcoholic Steatohepatitis (NASH)
Primary: Change From Baseline in Alanine Aminotransferase (ALT) at Week 12 — -22.06; -30.41; -8.77 Units per Liter (U/L) — p=0.075
Phase 3 N=97 Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL
Postoperative Pain Management
Primary: Area Under the Plasma Concentration-versus-time Curve (AUC) 0 to Infinity — 14246.1; 5709.4; 11569.5; 26164.0 ng*h/mL
N/A N=50 Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR)
Coronary Heart Disease · Metabolic Syndrome · Diabetes Mellitus
Primary: Change in Global Myocardial Blood Flow in Response to Vasodilator — 0.05; -0.145 percentage change in CFR
N/A N=132 Postoperative Environment on Pain Following Pelvic Reconstructive Surgery
Postoperative Pain
Primary: Visual Analog Scale (VAS) Score for Pain — 28.0; 24.5 millimeter (mm) — p=0.57
Phase 2 N=150 Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Dry Eye Syndromes · Keratoconjunctivitis Sicca
Primary: Bulbar Conjunctival Hyperemia — 1.22; 1.36 score on a scale
N/A N=130 Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction
Esophageal Carcinoma
Primary: Overall Survival — 12; 11; 13 participants